RXI-109: Phase IIa started

RXi began the single-blind, U.S. Phase IIa RXI-109-1401 trial to evaluate intradermal RXI-109 in about 16 patients undergoing keloidectomy. Patients will receive RXI-109 at 1 excised keloid site and placebo at a second excised keloid site. The company said it expects "to get an early first impression of a possible clinical effect" by year end. ...